R

Rhythm Pharmaceuticals

Commercializes MC4R-targeted therapies for rare obesity

Territory Manager

Full-Time
$135k - $215k+ Discretionary annual bonus + Restricted stock units
Senior
Seattle, WA, USA
HybridField-based territory role covering Washington, Oregon, northern Idaho, Wyoming, and Montana; candidates must be based in Seattle or San Francisco and travel up to 80%.
Sales & Account ManagementField Sales

About the job

Requirements
  • At least 6 years of specialty pharmaceutical and/or biotechnology sales experience.
  • Proven track record of consistent performance in complex markets with diverse customer segments.
  • Ability to command scientific data and communicate it effectively to different health care professional audiences.
  • Strong understanding of healthcare regulatory and enforcement environments.
  • Strong interpersonal and communication skills, including productive customer engagement using active listening.
  • Ability to adapt and thrive in a fast-paced, dynamic environment and to respond quickly to evolving business needs while driving results toward shared goals.
  • Strong critical-thinking skills and a solution-oriented mindset.
  • Strong organizational and operational skills, attention to detail, and sound business judgment.
  • Ability to travel up to 80% as necessary.
  • Must be based in a centralized location in the Northwest territory, specifically San Francisco or Seattle, with easy access to transportation and airports.
Responsibilities
  • Execute disease and branded education for target health care professionals in alignment with company priorities and direction.
  • Develop strong relationships with experts and target specialists in the assigned geography, ensuring delivery of clinically focused messages.
  • Collaborate with the patient services team to educate prescribers about enrollment processes and patient support tools and resources; respond to requests for physician or medical practice education to improve medication adherence.
  • Support marketing-driven educational webinars.
  • Collaborate with the Medical Science Liaison to ensure requests for medical information beyond the Territory Manager scope are appropriately submitted.
  • Comply with company compliance parameters and code of conduct standards.
  • Conduct disease and/or branded education at applicable national, regional, or local industry congresses.
  • Accurately capture and report data in the customer relationship management system.
  • Participate in ongoing training to improve skills and optimize execution against yearly objectives.
  • Maximize the budget allocated to the geographic territory to support strategies and tactics that achieve business goals.
  • Complete corporate and administrative responsibilities, including healthcare compliance training, expense reports, and other assignments by established deadlines.
Desired Qualifications
  • Rare disease experience is strongly preferred.

About the company

R

Rhythm Pharmaceuticals

View
Website

Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2008

Get referred to Rhythm Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 product revenue hit $71.3 million, up 19% sequentially.
  • More than 400 acquired-HO start forms came from roughly 300 prescribers by June 30, 2026.
  • AJ Joshi became chief medical officer on August 17, 2026, strengthening late-stage execution.

What critics are saying

  • Rhythm depends on IMCIVREE; August 2026 revenue still came entirely from one drug.
  • RM-718 and bivamelagon must succeed after 2026 data; failure leaves no next growth engine.
  • Hypothalamic obesity launches in Japan and Europe need reimbursement speed; delays hit 2027 demand.

What makes Rhythm Pharmaceuticals unique

  • Rhythm owns the only approved MC4R franchise for rare genetic obesity, built since 2008.
  • IMCIVREE won Japan MHLW approval on August 24, 2026, extending global rare-obesity reach.
  • Rhythm published a Bardet-Biedl diagnostic algorithm, improving patient identification for prescribers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options
  • Performance Bonus
  • Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

8%

2 year growth

2%
Yahoo Finance
Oct 13th, 2026
Rhythm launches IMCIVREE in Japan, the first approved therapy for acquired hypothalamic obesity

Rhythm Pharmaceuticals has launched IMCIVREE (setmelanotide) in Japan to treat acquired hypothalamic obesity. It is the first approved therapy for the condition in the country, and it is now on Japan's National Health Insurance drug price list. Japan's Ministry of Health, Labour and Welfare approved the drug in August. The approval rested on the Phase 3 TRANSCEND trial of 142 patients, which met its primary endpoint with an 18.8% placebo-adjusted reduction in body mass index. Rhythm, based in Boston, estimates that 5,000 to 8,000 people in Japan live with the condition. "This launch marks an important advancement for people living with acquired HO in Japan," said Yann Mazabraud, executive vice president and head of international at Rhythm.

Yahoo Finance
Sep 12th, 2026
Druckenmiller's fund buys $22.6M stake in rare obesity treatment maker Rhythm Pharmaceuticals

Stanley Druckenmiller's Duquesne Family Office disclosed new positions in over 40 stocks in its second quarter 13F filing. Notable healthcare investments included 203,618 shares of Rhythm Pharmaceuticals worth $22.6 million and 356,600 shares of Definium Therapeutics worth $16.8 million. Rhythm Pharmaceuticals develops treatments for hypothalamic obesity, currently the only approved drug for this condition. The company estimates approximately 10,000 US patients have acquired hypothalamic obesity, with similar numbers in Europe and 5,000 to 8,000 in Japan. Second-quarter revenue increased 47% year over year, whilst US revenue jumped 38% sequentially. The company remains unprofitable despite revenue growth and held $330.9 million in cash at quarter end, expected to fund operations for at least 24 months.

Yahoo Finance
Aug 24th, 2026
Japan approves Imcivree for acquired hypothalamic obesity, launch expected by end of 2026

Rhythm Pharmaceuticals has received approval from Japan's Ministry of Health, Labour and Welfare for IMCIVREE (setmelanotide) to treat patients with acquired hypothalamic obesity (HO). This marks the first therapy approved in Japan for this condition. The approval was supported by the Phase 3 TRANSCEND trial involving 142 patients, including a Japanese cohort. The study met its primary endpoint with an 18.8% placebo-adjusted reduction in body mass index. Rhythm estimates 5,000 to 8,000 people are living with acquired HO in Japan. The company expects to launch IMCIVREE before the end of 2026, pending final pricing determination. Acquired HO is characterised by accelerated weight gain following hypothalamic injury, often resulting from craniopharyngioma, astrocytoma, or other hypothalamic-pituitary tumours.

Yahoo Finance
Aug 17th, 2026
Rhythm Pharmaceuticals appoints Manher Joshi as chief medical officer

Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.

Associated Press
Aug 11th, 2026
Rhythm Pharmaceuticals' IMCIVREE receives UK approval for acquired hypothalamic obesity treatment

Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.